The clinical application of self-inactivating (SIN) retroviral vectors has been hampered by the lack of reliable and efficient vector production technologies. To enable production of SIN g-retroviral vectors from stable producer clones, a new PG13-based packaging cell, known as PG368, was developed. Viral vector expression constructs can be reliably inserted at a predefined genomic locus of PG368 packaging cells by an Flp-recombinasemediated targeted cassette exchange (RMCE) reaction. A new, carefully designed vector-targeting construct, pEMTAR-1, eliminated the co-packaging of the selectable marker gene used for the identification of successful recombination at the predefined genomic locus and thus, improved the safety of the production system. Selected clones produced vector supernatants at consistent titers. The targeted insertion of therapeutically relevant SIN vectors for chronic granulomatous disease and X-linked severe combined immunodeficiency into PG368 cells results in stable titers within the range necessary for clinical application. The production of retroviral SIN vectors from stable clinical-grade producer cells is feasible and will contribute to the safe production and application of SIN g-retroviral vectors for clinical trials.
Introduction
Retroviral-mediated gene therapy has been shown to be an efficient treatment option for a number of inherited blood disorders. 1 Patients with X-linked severe combined immunodeficiency (SCID-X1 2 ), adenosine deaminase deficient SCID (ADA-SCID 3, 4 ) and chronic granulomatous disease (CGD 5 ) have clearly benefited from gene therapy treatment, and almost all treated patients have shown phenotypic correction of the disease for at least several months.
However, the occurrence of severe adverse events such as leukemias in SCID-X1 patients 6 and myelodysplastic-like syndromes in CGD patients (M Grez, personal communication) has shown the limitations of the current generation of vectors. Vector-related side effects can be significantly reduced by relatively modest changes in vector architecture. [7] [8] [9] In this respect, several studies have shown that self-inactivating (SIN) vectors, which harbor a deletion of the promoter/enhancer elements in the LTR, do have a more favorable biosafety profile compared with conventional LTR-driven retroviral vectors. [8] [9] [10] Self-inactivating retroviral vectors have been constructed on the basis of lentiviral (for example, human immunodeficiency virus-1, simian immunodeficiency virus) 11, 12 and g-retroviral (MLV) backbones. [13] [14] [15] Production of SIN vectors is routinely accomplished by transient cotransfection of packaging and transfer vector plasmids into HEK293T cells. 11, 16 Although transient production is more flexible and avoids the longer time required to generate stable vector-producing cell lines, stable producer clones still have theoretical advantages, such as higher reproducibility, predictability of viral vector output and the possibility of cell banking.
Stable packaging cell lines are usually generated by transducing packaging cells with LTR-driven retroviral vectors, followed by a selection of the best producers. However, this procedure is not feasible for SIN vectors, as the transduction of a SIN vector would result in the inactivation of the 5 0 LTR promoter, which is necessary to generate vector genomic RNA used for packaging. Therefore, the SIN vector, including an intact 5 0 LTR with active promoter/enhancer elements, has to be transfected as a DNA plasmid into the packaging cells. However, this procedure results in unpredictable and variable titers.
Site-specific recombinases such as Cre and Flp have the capability to integrate foreign DNA sequences into the predefined loci. The RMCE (recombinase-mediated cassette exchange technology) (reviewed in Bode et al. 17 and Wirth et al. 18 ), has the potential to replace an integrated cassette, flanked by two hetero-specific/ noninteracting recognition sites (FRT) with a second cassette by homologous recombination at the FRT sites. RMCE-mediated targeted integration allows for the rapid generation of retroviral producer cells with high, reproducible and predictable titers. This technology was used previously to generate two packaging cell lines, Flp293A and 293FLEX, providing either amphotropic or GALV-pseudotyped envelopes for the production of g-retroviral vectors. 19, 20 In this study, we describe the use of the RMCE-based tagging/targeting procedure 19, 21 to generate a PG13-based packaging cell line, 22 known as PG368, for the production of GALV-pseudotyped SIN g-retroviral vectors. We chose PG13 as the starting material as this line has successfully been used to establish clinical-grade retroviral vector producer clones for recent clinical trials. 5, 23 We established a tagged locus in PG13 cells under fully controlled conditions. This will allow the transfer of the PG368 packaging cells into a GMP process for production of g-retroviral vectors. Optimization of SIN vector architecture led to the selection of the most suitable design for SIN-vector production in PG368 cells after targeting the tagged locus. We used this system for generating stable producer clones for therapeutic vectors aimed at correcting CGD and X-linked severe combined immunodeficiency (SCID-X1).
Results and Discussion
Establishment of a targetable PG13-based packaging cell line
The experimental setup for establishing a targetable packaging cell line is shown schematically in Figure 1a . In essence, PG13 packaging cells were transduced with the retroviral 'tagging' vector, TAGeGFP, 19 at an MOI of 0.02 to ensure single copy integration. About 100 clones were obtained after hygromycin B selection. Transduced clones, termed 'PG368' hereafter, were tested for production of the tagging vector (Figure 1b) . Among the PG368 clones, four generated infectious particles in the range of B1 Â 10 6 IP ml
À1
, namely clone nos 21, 23, 69 and 86. All four clones did not survive G418 selection, indicating that at the 'tagged' loci no activation of the neomycin resistance gene had occurred by transcriptional readthrough.
These four PG368 clones were subsequently targeted with pEMTAR.MFGeGFP, 19 a plasmid containing the Fn and F5 recombination sites (FTR sites 24 ) and an LTRdriven MFG-based retroviral vector 25 with enhanced green fluorescent protein (eGFP) as a marker gene and an IRES-coupled 'atg' start codon downstream of the 3 0 LTR (Figure 1a ). Cells were cotransfected with a plasmid encoding for the Flp-recombinase to allow site-specific recombination at the FRT sites. Flp-mediated recombination resulted in the loss of hygromycin resistance and activation of the NeoR gene. Five targeted clones for each of the four selected PG368 clones were isolated after G418 selection and tested for vector production ( Figure 1c) . The most consistent and robust titers were obtained from the PG368#23 packaging cell clone, with highly homogeneous titers differing only by twofold . A primary and secondary seed bank of the PG368#23 producer clone was generated and is referred to as the PG368 cell line hereafter.
High-titer SIN-vector production in PG368 producer cells depends on promoter activity and vector cargo Next, we constructed a series of pEMTAR-based exchange plasmid vectors containing safety-improved SIN retroviral vector backbones as described by Schambach et al. 15, 26 These vectors termed 'SIN11-SF,' 'SCS11-SF,' 'SRS11-SF' and 'SERS11-SF' differ only in the enhancer/ promoter combination (P2) driving the expression of the viral genomic mRNA. All these vectors contained an internal SFFV-derived promoter (P1) driving the eGFP expression. In addition, we tested a second line of retroviral backbones, termed 'ES.1-SF' and 'ES.1-EFS,' which contained a CMV/MLV-hybrid promoter at the 5 0 LTR in addition to an enlarged packaging region 27, 28 and either an internal SFFV promoter or the elongation factor short promoter driving the eGFP expression ( Figure 2a ). Stable PG368 cell clones were generated as described above and titers were determined on HT1080 cells ( titers obtained from the SIN11-SF producer clones were similar to those of the ES1-SF and ES1-EFS clones, despite much lower amounts of genomic RNA in the latter two. This observation is suggestive of packaging constraints related to vector architecture and promoter interference as described previously. 26 The introduction of the same vectors into the two independent loci in HEK293-based modular Flp293A cells 19 and 293Flex cells 20 revealed highest titers for the SERS11-SF and the ES.1-SF constructs (Gama-Norton et al., submitted 42 ). This may indicate that the generation of high-vector titers depends on P2-driven viral genome expression and on the influence of P1 on P2 (see also Schambach et al. 26 ). In addition, the strength of P1 and P2 may depend on cellular context (for example, human vs mouse cells) adding another level of complexity to the system.
Besides the genomic transcripts, transcripts initiated at P1 were evident in all producer cells and were most abundant in SCS11-SF and SRS11-SF producer cells ( Figure 2c ). In fact, this may indicate a strong negative interference for genome synthesis with particular promoter configurations and/or still unknown structural constraints and cellular context may influence SIN g-retroviral titers. In addition, a splice transcript was detected in ES1-SF and ES1-EFS producer cells, which was attributed to the presence of splice donor and acceptor site in the enlarged leader region used in these vectors. As bona fide insertions into the TAGeGFP-tagged chromosomal loci by pEMTAR-derived plasmids results in the activation of the neomycin-resistant gene by readthrough mechanisms from transcripts starting at P1 and/ or P2 (Figure 3a) , we asked whether transcripts containing the neomycin resistance gene could be co-packaged with the transfer vector. To test this possibility, we used vector supernatants produced by different PG368 producer clones after FLP-mediated recombination for the transduction of HT1080 cells (Figure 3b ). Transduced cells were cultured in the presence of G418, and neomycin-resistant colonies were counted 10-14 days thereafter. As shown in Figure 3c , all producer clones generated infectious vector particles containing the neomycin resistance gene. The number of neomycinresistant colonies varied among the different vector supernatants and was the highest in HT1080 cells transduced with vector supernatants obtained from PG368/SIN11-SF producer cells (1 Neo-transfer vector particle per 2800 infectious particles). Interestingly, the inclusion of a termination enhancer (2 Â SV40 USE, 2 Â SV) 29 within the viral 3 0 LTR reduced the number of Neo-transfer vector particles (NTVP). An even greater reduction in the NTVP numbers was seen in supernatants obtained from PG368/ES1-SF producers, although the reason for this remains unclear.
The generation of neomycin-resistant colonies from readthrough transcripts starting at P2 potentially could lead to the restoration of the LTR U3 function (Figure 3a) . Therefore, we used supernatants from PG368/SIN11-SF producers to transduce the packaging cell line FLYA13. After G418 selection, the supernatants from NeoR FLYA13 cells were used to transduce HT1080 cells. We found that two out of three neomycin-resistant FLYA13 clones generated neomycin-resistant colonies in transduced HT1080 cells proving that the configuration of the pEMTAR target exchange plasmid leads with high frequency to the inclusion of a fully functional LTR in the reverse-transcribed product (data not shown). In conclusion, these findings exclude the use of pEMTARbased target exchange plasmids for the production of retroviral SIN-vectors suitable for clinical use.
Redesign of the pEMTAR-targeting construct overcomes transfer of the neomycin resistance gene and restoration of U3 function
To circumvent the problems associated with pEMTAR, we developed a bidirectional design for the targeting construct in which the viral vector was placed in antisense orientation to the neocassette at the tagged locus. Furthermore, the IRES element in pEMTAR was replaced by the constitutive human PGK promoter (P3) rendering activation of the neomycin resistance independent from the expression of the viral genome. This new targeting construct was named pEMTAR-1 (Figure 4a) .
We used pEMTAR-1 to introduce the SIN11-SF vector into PG368 cells. Vector containing supernatants from NeoR cells were tested for the cotransfer of NTVP. No neomycin-resistant colonies were obtained after transduction of HT1080 cells with 1.2 Â 10 7 SIN11-SF vector particles. We believe that the number of infectious particles tested is sufficiently high to exclude the generation of NTVP also in large-scale productions, as we saw more than a four-log reduction in the transmission of neomycin resistance by pEMTAR-1.SIN11-SF supernatants in comparison with pEMTAR.SIN11-SF supernatants. Taken together, redesign of the targeting construct improved safety; however, at the expense of a 2-3-fold reduction in the virus titer (Figure 4c) .
Next, we asked whether further modifications in pEMTAR-1 would lead to increased vector titers, as the cluster of the LTR and housekeeping promoters in pEMTAR-1 might result in negative promoter interference at P2 and consequently in low titers (Figure 4a ). 
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To approach this, we considered the promoter interaction between the internal P1 and the external P2 promoter of the viral vector not to be relevant, as type, spacing and orientation of the two promoters were identical in pEMTAR and pEMTAR-1. Therefore, we focused our attention on the interaction between P2 and P3, as P2 is relevant for the production of packageable genomic RNA. Several strategies were tested to avoid promoter interference between P2 and P3. First, a chicken HS4 insulator sequence element was included between P2 and P3 as the HS4 insulator has been shown to have enhancer blocking activity and to shield promoters from adjacent enhancers. 30 Second, we replaced P2 by a tetinducible promoter, and finally, we replaced P3 by a CMV-minimal promoter thereby transforming P2 into a bidirectional promoter (Figure 4b ). All producer clones derived from modified pEMTAR-1 backbones produced virus titers in the range of 5-8 Â 10 5 IP ml À1 (except the construct containing the HS4 insulator element), and thus slightly lower than the ones obtained after pEMTAR-mediated recombination (Figure 4c) . Again, northern blot of total RNA from these clones showed lower genomic RNA abundance for pEMTAR-1 constructs compared with pEMTAR, in agreement with the observed titer differences (Figure 4d ).
Generation of stable PG368 packaging cells for clinically relevant g-retroviral vectors
Having defined an improved targeting system, we evaluated this system in the context of clinically relevant therapeutic vectors. For this purpose, two therapeutic vectors aimed at the correction of CGD (see MorenoCarranza et al. 31 and M Grez, unpublished data) and Xlinked severe combined immunodeficiency (SCID-X1 32 ) were inserted into pEMTAR-1 and targeted into PG368 packaging cells. The internal P1 promoter in the SIN11-SF vector was replaced by either the EFS promoter or the c-fes promoter (M Grez, unpublished data), and eGFP was replaced by either a codon-optimized gp91phox cDNA (for CGD) 31 or the wt IL2Rgc-chain cDNA (for SCID-X1) 32 ( Figure 5a ). The titer of the best PG368 producer clones for SIN11(fes-gp91) and SIN11(EFS-gc) was similar and ranged between 1.0 Â 10 5 and 4.1 Â 10 5 IP ml
À1
, which is B5-to 20-fold lower than the titer detected for SIN11-SF (2 Â 10 6 IP ml
) after pEMTAR-mediated targeted exchange reaction (Figure 5b ). Titer reduction was not caused by low levels of packageable genomic RNA, as no correlation was found between the amount of vector genomic RNA found in the producer cells and the estimated titers (Figure 5c ). For example, the amount of genomic RNA found in PG368/SIN11(fes-gp91) was twofold higher than that of PG368/SIN11(SF-eGFP), whereas the titer generated by PG368/SIN11(fes-gp91) was at least fivefold lower than that of PG368/SIN11 (SF-eGFP). Clearly, the promoter configuration or other vector cargo features seem to influence titer, for example, by promoter interference, mRNA stability or accessibility of the packaging signals to the retroviral nucleocapsid proteins.
Interestingly, the highest amount of vector genomic RNA was found in the PG368-PGK.SIN11(fes-gp91) producer clone. The vector backbone in this construct includes a myeloid-specific promoter at P1 (c-fes), which is not active in murine fibroblasts. One may speculate that the presence of a weak promoter at P1 may allow for maximal expression from P2 at the targeted locus, although this did not lead to a concomitant increase in viral titers.
In summary, both therapeutic vectors could be produced at reasonable titers (1-4 Â 10 5 IP ml
) and after concentration, pre-loading these supernatants should be useful for the transduction of hematopoietic stem cells in the context of clinical trials.
Conclusion
The RMCE technology, which allows the introduction of a vector genome at a predefined chromosomal The table below compares the relative abundance of the P2-expressed genomic transcript and the titers observed for each producer clone analyzed. The titer and the genomic transcript level of pEMTAR-SIN11 is set to 100%. For detection of genomic and internal transcripts, the blot was probed with enhanced green fluorescent protein (eGFP). For normalization of RNA input, the blot was reprobed with glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Stable production of SIN vectors R Loew et al locus, makes vector production more predictive and noteworthy and greatly reduces the time necessary to define the best producer clone for a particular vector. In this study, we designed a bidirectional exchange construct (pEMTAR-1), which greatly improved the safety of vector production by elimination of the readthrough-based selection of targeted producer clones and now allows the use of the targeted exchange technology together with the tagged PG368 packaging cells to establish stable producer clones for clinically relevant vectors. Moreover, as the tagging and selection process of the PG368 cells was carried out under highly controlled conditions, this cell line can be readily transferred into a GMP process for the production of such vectors.
Our results identified two major constraints for efficient SIN-vector production: (1) The external P2 promoter, which provides the genomic transcript of the vector. This problem was solved by the use of a highly active P2 promoter (MPSV-U3 promoter), providing large quantities of vector genomes in PG368. (2) Effects of the vector cargo also affect viral titers, possibly through promoter interference, mRNA stability and/or accessibility of packaging signals. In retroviral SIN vectors, concerns related to the presence of an extended packaging region 25, 26 are less eminent than in LTR vectors, because the SIN design reduces the risk of the formation of replication-competent retrovirus and the extended packaging region is not contained in the therapeutic transcript initiated by the internal promoter. Thus, further vector developments should address the issue of efficient packaging of vector genomes regardless of their promoter and cargo configurations.
Materials and methods

Cell culture
293T (ATCC no. CRL-11268), Ht1080 (ATCC no. CCL-121), PG13 (ATCC no. CRL10686), T-Fly A 33 and PG368 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% heat-inactivated fetal calf serum (PAA, Pasching, Austria) at 37 1C in a humified atmosphere with 5% CO 2 . Cultures were propagated at logarithmic growth and were split at 70-80% confluency.
Plasmid constructs
The retroviral SIN-vectors SIN11-SFgfp, SCS11-SFgfp, SRS11-SFgfp and SERS11-SFgfp have been described previously. 26 The retroviral SIN-vectors of the pES.1 Stable production of SIN vectors R Loew et al series were similar to the previously described SFG-ECT2-luc vector 34, 35 with the following modifications: (1) deletion of the ATG codon within the psi+ region, (2) an altered 5 0 -promoter (CMV enhancer (À673/ À53) with minimal MLV promoter (À50/+1) hereafter known as cm-hybrid promoter) driving genomic RNA expression and (3) modification of the 3 0 LTR in which the DNA region around the TATA-box was modified to avoid initiation of transcription (details provided on request).
pEMTAR-1 was derived from pEMTAR and contains the vector genome in reverse orientation relative to the neomycin gene. Furthermore, the ECMV IRES present in pEMTAR was replaced by the human PGK promoter. 36 The pEMTAR-1.PGK.HS4.SIN11 contains a small insulator fragment (HS4 30 ) of the chicken b-globin gene, inserted between P2 and P3 promoters (Figure 4b) . The modification in pEMTAR-1.PGK.Tet11 was the replacement of the PGK promoter by a tet-regulatable promoter (Ptet-1 37 ), and in pEMTAR-1.bi-SIN11, the PGK promoter was replaced by a CMV minimal promoter (À53/+75).
The SIN g-retroviral vectors, SIN11(fes-gp91) and SIN11(EFS-gp91), were derived from SERS11.SF.gp91.W 31 by replacing the SFFV LTR by a 500-bp DNA fragment obtained from the human c-fes promoter and the intronless version of the elongation factor 1a promoter (REF), respectively. The SERS11(EFS-gc) viral vector has been described previously, 32 and was used for construction of the SIN11(EFS-gc) retroviral vector transferred by pEM-TAR-1 (introduction of vectors into pEMTAR or pEMTAR-1 was done using standard molecular biology techniques).
Transient vector production
TAGeGFP vector supernatants were generated by transient transfection on 293T cells with a DNA mixture consisting of 5 mg pHIT60 (gag/pol expression plasmid 38 ), 5 mg pczVSV-G (VSV-G envelope expression plasmid 39 ) and 5 mg of the tagging vector 19 using lipofection (TransIt 293 reagent, Mirus, Madison, WI, USA) as recommended by the supplier. Supernatants were titrated on HT1080 cells after one freeze/thaw cycle. Three to five serial dilutions were used to determine viral vector titer on the basis of eGFP-positive cells.
Generation of tagged packaging cells
Transiently produced TAGeGFP vector supernatants were used to transduce PG3C11 cells at an MOI of 0.02. Transduced cells were selected in hygromycin-containing media (75 mg ml À1 , Invitrogen) for 5-7 days. Approximately 100 clones were tested for vector production and the 20 best clones were selected for detailed analysis. Finally, four clones (PG368, no. 21, no. 23, no. 69 and no. 86) were selected and tested for vector production by targeted exchange reaction.
Generation stable producer clones for SIN g-retroviral vectors by targeted exchange reaction PG368 producer clones were established by Flp-recombinase-mediated targeted exchange reaction after transient cotransfection of the targeting constructs, pEMTAR or pEMTAR-1. Briefly, 5 Â 10 4 PG368 cells were transfected with a DNA mixture consisting of 4 mg Flp-recombinase expression plasmid (pSV-Flpe 19 ) and 1 mg of the pEMTAR-or pEMTAR-1 exchange plasmid. Twenty-four hours later transfection cells selection with G418 (400 mg ml
À1
) was started and individual clones were expanded under continued selection.
Titration of viral vectors
All titrations of vector supernatants were performed on HT1080 cells by limiting dilution. Briefly, 2 Â 10 5 HT1080 cells were transferred into 6-well dishes the day before transduction and transduced using standard methods. Cells were harvested for fluorescence-activated cell sorting analysis on day 5. Titration of the therapeutic SIN-vectors, SIN11(fes-gp91) and SIN11(EFS-gc), was performed in a similar manner, but titers were determined by Q-PCR using WPRE (woodchuck hepatitis virus posttranscriptional regulatory element) sequences. Genomic DNA was prepared using the QIAmp DNA Blood mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Primer/probe sets were designed by the Primer Express software program (Applied Biosystems, Darmstadt, Germany). The 5 0 -oligo (PRE-1f) was 5 0 -AGCACACCACGCCACGTT, the 3 0 -oligo (PRE-1r) was 5 0 -CCTTGTATAAATCCTGGTTGCTGTCT and the probe (PRE-1p) was 5 0 -FAM-ACGGACAACGGGCCACAACT CCTCT-TAMRA. For reference, the primer/probe set for detection of human erythropoietin (Hepo) was used. The 5 0 -oligo (Hepo-f) was 5 0 -CTGCTGCCAGCTTTGGAGTA CACTA, the 3 0 -oligo (Hepo-r) was 5 0 -GAGATGCCAGAG TCAGATACCACAA and the probe (Hepo-p) was VIC- Northern analysis of total RNA Total RNA was isolated using the acidic phenol method 40 and subjected to non-radioactive northern analysis according to a previously published method, 41 except that CPD-Star (Tropix, Bedford, MA, USA) was used as substrate for chemiluminescence detection. Rat GAPDH (glyceraldehyde 3-phosphate dehydrogenase) served as internal standard. Probes were biotin labeled during PCR amplification. Detection of the relative mRNA steady-state levels was achieved after exposure of the gel to X-Ray film (Kodak Bio-Max light, Sigma, Munich, Germany). RNA size markers were from Promega (Mannheim, Germany). Oligonucleotides used for hybridization were: for GAPDH, sense: 5 0 -AATGCATCCT GCACCACCAAC, antisense: 5 0 -GCCATATTCATTGTC ATACCAGG; for eGFP, sense: 5 0 -TTCAGCGTGTCCGGC GAG, antisense: 5 0 -TCCTCGATGTTGTGGCGG; for WPRE, sense: 5 0 -GGGCTGCAGGATcCGAGCATCTTACG, antisense: 5 0 -GATATCTCCGCAGGAAGATCTCGACGTC AGCT; for MLV gag/pol, sense: 5 0 -AGACGGCACCTTTA ACCG, antisense: 5 0 -GGTGATGAGAACAGACTC. The densitometric analysis was carried out using the NIH-1.57 software (public domain). Signal intensity is expressed as mean density of identical blot areas.
